Log In

 

Company Name : Boehringer Ingelheim

Friday, February 17, 2017 9:15AM IST (3:45AM GMT)

(BW)(BOEHRINGER-INGELHEIM)

US FDA Expands Approval of Tiotropium Respimat® for Maintenance Treatment of Asthma in Children


Tiotropium Respimat® (marketed as SPIRIVA® Respimat®) now approved in US as asthma maintenance treatment for people aged 6 years and older1FDA approval expands use of tiotropium Respimat® in the US to a broad age range of people across all asthma severitiesTiotropium Respimat® is currently NOT APPROVED for use in children and adolescents with asthma outside of the US


Ingelheim, Germany

Boehringer Ingelheim announced that the U.S. Food and Drug Administration (FDA) approved tiotropium Respimat® (marketed as SPIRIVA® Respimat®) for the long-term, once-daily maintenance treatment of people with asthma aged 6 years and older who continue to experience symptoms despite their other maintenance therapy – usually either inhaled corticosteroid (ICS) alone, or a combination of inhaled corticosteroids/long-acting beta agonists (ICS/LABA).1 This approval reflects the comprehensive tiotropium Respimat® paediatric clinical trial programme, involving 905 children aged 6-11 years, conducted by Boehringer Ingelheim.2,3,4

 

Tiotropium Respimat® is part of a class of medicines called long-acting muscarinic antagonists (LAMA) and is the only one of its kind approved for asthma. It works differently from other treatment options by complementing other maintenance therapies (usually ICS/LABA) to open the airways, which helps people breathe better and reduces asthma attacks, also known as exacerbations.

 

“This FDA approval expands the US indication for tiotropium Respimat® to a broad range of patients, including children, adolescents and adults in the US who may suffer from symptomatic asthma despite taking other maintenance therapies,” said Dr William Mezzanotte, Vice President and Head of Respiratory Medicine at Boehringer Ingelheim. “The expansive paediatric programme within the comprehensive UniTinA-asthma® clinical trial programme, reflects the ongoing commitment of Boehringer Ingelheim to providing innovative solutions for children and adults living with asthma and other serious respiratory diseases.”

 

In the comprehensive, large-scale UniTinA-asthma® clinical trial programme, tiotropium Respimat® demonstrated proven efficacy and safety as an add-on therapy for children, adolescents and adults with asthma.1,5,6,7,8,9,10,11,12,13

 

Tiotropium Respimat® is delivered via Respimat®, the only inhaler that actively* delivers a propellant-free mist, meaning a person just needs to take a slow deep breath in for the medication to go deep into the lungs.14,15,16,17,18,19,20

 

Previously, in September 2015, tiotropium Respimat® was approved in the US for the long-term, once-daily, prescription maintenance treatment of asthma in people aged 12 and older.1 Tiotropium Respimat® was approved in the EU in 2014 as an add-on therapy for adults (aged 18 and older) with asthma.

 

For more information please visit http://www.boehringer-ingelheim.com/press-release/ASTHMA-FDA-Expanded_Approval_of_Tiotropium_Respimat®

 

Intended audiences:

 

This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products varies from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.

 

-----------------

 

SPIRIVA® Respimat® is currently NOT APPROVED for use in children and adolescents under 18 years of age in the EU. SPIRIVA® Respimat® has been approved for use in asthma in over 50 countries, including in the EU, U.S. and Japan. The label varies by country. Please refer to the local product information.

 

* Respimat® delivers a metered dose of medication in a mist at the push of a button not requiring the force from the patient’s inhalation

 

 

 

 


Click here for Media Contact Details
CONTACTS : Boehringer Ingelheim Corporate Communications Media + PR Dr. Kristin Jakobs Phone: +49 6132 77 144553 Mobile: +49 1516 89 47444 Fax: +49 6132 77 6601 Email: press@boehringer-ingelheim.com

More News from Boehringer Ingelheim

22/06/2017 11:20AM

New data reveal high rates of stroke history in asymptomatic atrial fibrillation patients

Boehringer Ingelheim today announced findings from GLORIA™-AF which show that people with non-valvular atrial fibrillation (AF) with few or no symptoms are more likely to have had a stroke prior to AF diagnosis ...

14/06/2017 7:57PM

Boehringer Ingelheim presents phase III results demonstrating clinical equivalence of adalimumab biosimilar candidate to HUMIRA®

Boehringer Ingelheim announced today results from the pivotal Phase III VOLTAIRE®-RA1 study, confirming that its adalimumab biosimilar candidate BI 695501 and HUMIRA®* have similar efficacy, safety and ...

05/06/2017 9:50PM

Encouraging Phase II survival data for nintedanib in malignant pleural mesothelioma presented at ASCO 2017

Boehringer Ingelheim today announced that Phase II results from LUME-Meso, a randomised, double-blind, placebo-controlled trial, have been presented as part of an Oral Abstract Session at the 2017 Annual Meeting of the ...

Similar News

24/06/2017 1:00PM Image

FICCI Organizes TANCARE to Promote Tamil Nadu as a Global Healthcare Destination

The Federation of Indian Chambers of Commerce and Industry (FICCI) organized TANCARE, a one day healthcare conference in Hotel Hilton here, to promote Tamil Nadu as a global healthcare destination. The event which ...

No Image

23/06/2017 7:15PM

Taro Annual Report on Form 20-F Available for Fiscal Year Ended March 31, 2017

Taro Pharmaceutical Industries Ltd. (NYSE:TARO, “Taro”) announced that its Annual Report on Form 20-F for the fiscal year ended March 31, 2017, filed with the Securities and Exchange Commission (the ...